These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

573 related items for PubMed ID: 11907807

  • 1. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
    Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H.
    Acta Neuropathol; 2002 Mar; 103(3):267-75. PubMed ID: 11907807
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
    Huang L, Jiang T, Yuan F, Li GL, Xu LX, Cui Y.
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
    [Abstract] [Full Text] [Related]

  • 4. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
    Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, Schüler D, Probst-Hensch NM, Yasargil MG, Yonekawa Y, Lütolf UM, Kleihues P, Ohgaki H.
    Acta Neuropathol; 2004 Jul; 108(1):49-56. PubMed ID: 15118874
    [Abstract] [Full Text] [Related]

  • 5. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
    Qu M, Olofsson T, Sigurdardottir S, You C, Kalimo H, Nistér M, Smits A, Ren ZP.
    Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
    [Abstract] [Full Text] [Related]

  • 6. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas.
    Thon N, Eigenbrod S, Grasbon-Frodl EM, Ruiter M, Mehrkens JH, Kreth S, Tonn JC, Kretzschmar HA, Kreth FW.
    J Neuropathol Exp Neurol; 2009 Nov; 68(11):1219-28. PubMed ID: 19816195
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, Fujimaki T, Hojo S, Kubo O, Ide T, Usui M, Ochiai C, Ito S, Takahashi H, Mukasa A, Asai A, Kirino T.
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India.
    Jha P, Agarwal S, Pathak P, Srivastava A, Suri V, Sharma MC, Chosdol K, Srivastava T, Gupta D, Gupta A, Suri A, Sarkar C.
    Cancer Genet Cytogenet; 2010 Apr 15; 198(2):126-34. PubMed ID: 20362227
    [Abstract] [Full Text] [Related]

  • 12. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas.
    Kitange G, Misra A, Law M, Passe S, Kollmeyer TM, Maurer M, Ballman K, Feuerstein BG, Jenkins RB.
    Genes Chromosomes Cancer; 2005 Jan 15; 42(1):68-77. PubMed ID: 15472895
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
    Xiong J, Liu Y, Wang Y, Ke RH, Mao Y, Ye ZR.
    Chin Med J (Engl); 2010 Dec 15; 123(24):3566-73. PubMed ID: 22166632
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
    Huang L, Jiang T, Yuan F, Li GL, Cui Y, Liu EZ, Wang ZC.
    Neuropathol Appl Neurobiol; 2009 Aug 15; 35(4):367-379. PubMed ID: 19019173
    [Abstract] [Full Text] [Related]

  • 17. Gene expression profiling and subgroup identification of oligodendrogliomas.
    Huang H, Okamoto Y, Yokoo H, Heppner FL, Vital A, Fevre-Montange M, Jouvet A, Yonekawa Y, Lazaridis EN, Kleihues P, Ohgaki H.
    Oncogene; 2004 Aug 05; 23(35):6012-22. PubMed ID: 15208679
    [Abstract] [Full Text] [Related]

  • 18. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
    Gadji M, Fortin D, Tsanaclis AM, Drouin R.
    Cancer Genet Cytogenet; 2009 Oct 05; 194(1):12-22. PubMed ID: 19737649
    [Abstract] [Full Text] [Related]

  • 19. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.
    Lavon I, Zrihan D, Zelikovitch B, Fellig Y, Fuchs D, Soffer D, Siegal T.
    Clin Cancer Res; 2007 Mar 01; 13(5):1429-37. PubMed ID: 17332285
    [Abstract] [Full Text] [Related]

  • 20. Molecular genetic evidence for subtypes of oligoastrocytomas.
    Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD, von Deimling A.
    J Neuropathol Exp Neurol; 1997 Oct 01; 56(10):1098-104. PubMed ID: 9329453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.